Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

JOHNSON & JOHNSON Director's Dealing 2004

Apr 28, 2004

29750_dirs_2004-04-28_ebe8bc9d-3fb7-4894-958c-16ee66f19408.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BARRIER THERAPEUTICS INC (BTRX)
CIK: 0001173657
Period of Report: 2004-04-28

Reporting Person: JOHNSON & JOHNSON (10% Owner)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Series A Convertible Preferred Stock $ Common Stock (2033333) Indirect
Series A Convertible Preferred Stock $ Common Stock (6300000) Indirect
Series B Convertible Preferred Stock $ Common Stock (50000) Indirect
Series C Convertible Preferred Stock $ Common Stock (512820) Indirect

Footnotes

F1: All of the outstanding shares of the Issuer's Series A Convertible Preferred Stock will convert automatically on a 2 for 1 basis into Common Stock of the Company prior to the Issuer's initial public offering.

F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by this subsidiary of the Reporting Person.

F3: All of the outstanding shares of the Issuer's Series B Convertible Preferred Stock will convert automatically on a 2 for 1 basis into Common Stock of the Company prior to the Issuer's initial public offering.

F4: All of the outstanding shares of the Issuer's Series C Convertible Preferred Stock will convert automatically on a 2 for 1 basis into Common Stock of the Company prior to the Issuer's initial public offering.